Based in New York and Boston, Gameto is a biotechnology company translating the impact of ovarian aging to develop solutions to improve fertility and stop the impact of menopause on female health. With some of the initial research conducted at the George Church lab at Harvard Medical School, Gameto has achieved ground-breaking results in creating the first human reprogrammed cells of the ovary (granulosa cells & oocytes precursors) to solve the problem of accelerated ovarian aging, which occurs up to five times faster than any organ in the body.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/10/22 | $23,000,000 | Seed and Series A |
Anne Wojcicki Bold Capital Brian Armstrong FJ Labs Future Ventures  Jack Abraham Lux Capital Overwater Ventures Plum Alley Investments Robert Nelsen SALT Fund TA Ventures | undisclosed |
| 05/29/24 | $33,000,000 | Series B |
BOLD Capital Partners Chelsea Hirschhorn Future Ventures Ingeborg Investments Insight Partners RA Capital Management Stacey Bendet Eisner Two Sigma Ventures | undisclosed |
